CU2 Stock Overview
Operates as a biomedical products company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.66 |
| 52 Week High | US$2.20 |
| 52 Week Low | US$1.38 |
| Beta | 1.2 |
| 11 Month Change | 7.81% |
| 3 Month Change | -16.61% |
| 1 Year Change | 1.97% |
| 33 Year Change | -72.61% |
| 5 Year Change | -56.62% |
| Change since IPO | -96.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 5.0% | 2.8% | 1.1% |
| 1Y | 2.0% | -5.7% | 7.2% |
Return vs Industry: CU2 exceeded the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: CU2 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| CU2 volatility | |
|---|---|
| CU2 Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CU2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CU2's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CU2 fundamental statistics | |
|---|---|
| Market cap | €309.37m |
| Earnings (TTM) | -€18.67m |
| Revenue (TTM) | €166.80m |
1.9x
P/S Ratio-17.1x
P/E RatioIs CU2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU2 income statement (TTM) | |
|---|---|
| Revenue | US$176.23m |
| Cost of Revenue | US$78.13m |
| Gross Profit | US$98.10m |
| Other Expenses | US$117.82m |
| Earnings | -US$19.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 55.66% |
| Net Profit Margin | -11.19% |
| Debt/Equity Ratio | 153.6% |
How did CU2 perform over the long term?
See historical performance and comparison